Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|October 15, 2020
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)Richard Dillon, Nicola Potter, Sylvie Freeman, et al.
Leukemia & Lymphoma|August 3, 2002
P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotypeMonica Pallis, Julie Turzanski, Yutaro Higashi, et al.
Blood|August 12, 2006
Polymorphisms in human homeobox HLX1 and DNA repair RAD51 genes increase the risk of therapy-related acute myeloid leukemiaMays Jawad, Claire Helen Seedhouse, Nigel Russell, et al.
Acta Haematologica|September 17, 2005
Future directions in multiple myeloma treatmentJ Anthony Child, Nigel Russell, Pieter Sonneveld, et al.
British Journal of Haematology|March 22, 2003
Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplicationsMonica Pallis, Julie Turzanski, Martin Grundy, et al.
Experimental Hematology|January 22, 2005
P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathwayJulie Turzanski, Martin Grundy, Shilli Shang, et al.
British Journal of Haematology|December 14, 2021
Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trialNigel Russell, Robert Hills, Lars Kjeldsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemiaClaire Seedhouse, Rowena Faulkner, Nadia Ashraf, et al.
Molecular Cancer Therapeutics|February 18, 2010
The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cellsMartin Grundy, Claire Seedhouse, Shilli Shang, et al.
BMC Pharmacology & Toxicology|June 18, 2013
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cellsMonica Pallis, Francis Burrows, Abigail Whittall, et al.
Pageof 12